SRY and breast carcinoma: IKKβ targeting reduces breast cancer mammosphere formation and tumourigenicity [41], and positively regulates Lin28B and SRY (sex determining region Y)-box 2 (SOX2) to promote breast cancer stemness [42] and reduces breast GD2+ TICs, thereby reducing metastasis [43].